Key result
Mybpc3 deficiency in mice causes HCM with ~12% longer mitral anterior leaflets versus wild-type.
Why the study?
MYBPC3 mutations cause hypertrophic cardiomyopathy frequently associated with mitral valve pathology, but the mechanisms of mitral valve enlargement are unclear.
MYBPC3 deficiency leads to structural mitral valve abnormalities and increased TGFβ activity independent of left ventricular outflow-tract obstruction, suggesting a paracrine mechanism in hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Preclinical Mybpc3-null data should not alter human HCM care; leaves open paracrine MV growth factor targeting for future study.
MYBPC3 mutations cause hypertrophic cardiomyopathy, which is frequently associated with mitral valve (MV) pathology. We reasoned that increased MV size is caused by localized growth factors with paracrine effects. We used high-resolution echocardiography to compare Mybpc3-null, heterozygous, and wild-type mice (n = 84, aged 3–6 months) and micro-CT for MV volume (n = 6, age 6 months). Mybpc3-null mice showed left ventricular hypertrophy, dilation, and systolic dysfunction compared to heterozygous and wild-type mice, but no systolic anterior motion of the MV or left ventricular outflow obstruction. Compared to wild-type mice, echocardiographic anterior leaflet length (adjusted for left ventricular size) was greatest in Mybpc3-null mice (1.92 ± 0.08 vs. 1.72 ± 0.08 mm, p < 0.001), as was combined leaflet thickness (0.23 ± 0.04 vs. 0.15 ± 0.02 mm, p < 0.001). Micro-CT analyses of Mybpc3-null mice demonstrated increased MV volume (0.47 ± 0.06 vs. 0.15 ± 0.06 mm3, p = 0.018) and thickness (0.35 ± 0.04 vs. 0.12 ± 0.04 mm, p = 0.002), coincident with increased markers of TGFβ activity compared to heterozygous and wild-type littermates. Similarly, excised MV from a patient with MYBPC3 mutation showed increased TGFβ activity. We conclude that MYBPC3 deficiency causes hypertrophic cardiomyopathy with increased MV leaflet length and thickness despite the absence of left ventricular outflow-tract obstruction, in parallel with increased TGFβ activity. MV changes in hypertrophic cardiomyopathy may be due to paracrine effects, which represent targets for therapeutic studies.
No takes yet. Share an insight, caveat, or question.
Judge et al. (2015) studied Hypertrophic cardiomyopathy (n=90). Mybpc3 deficiency vs. Wild-type mice was evaluated on Echocardiographic anterior leaflet length (adjusted for left ventricular size) (p=<0.001). Mybpc3 deficiency in mice caused hypertrophic cardiomyopathy with increased mitral valve anterior leaflet length compared to wild-type mice.
Synapse has enriched 10 related papers. Consider them for comparative context: